Amelioration of dextran sulfate sodium-induced colitis by neuropeptide Y antisense oligodeoxynucleotide

International Journal of Colorectal Disease

Volumn 25, Issue 9, 2010, Pages 1047-1053

  Pang, Xue Hua ^a   Li, Tian Ke ^a   Xie, Qin ^a   He, Fu Qian ^a   Cui, De Jun ^a   Chen, You Qin ^b   Huang, Xiao Li ^a   Gan, Hua Tian ^a  

^a SICHUAN UNIVERSITY   (China)

^b DALI UNIVERSITY   (China)

Author keywords

Antisense oligodeoxynucleotides (ODNs); Myeloperoxidase (MPO); Neuropeptide Y (NPY); Tumor necrosis factor (TNF) ; Ulcerative colitis (UC)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; NEUROPEPTIDE Y; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTRACOLON DRUG ADMINISTRATION; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ULCERATIVE COLITIS; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; COLITIS; DEXTRAN SULFATE; FLUORESCEIN-5-ISOTHIOCYANATE; INTESTINAL MUCOSA; MALE; NEUROPEPTIDE Y; OLIGODEOXYRIBONUCLEOTIDES; PEROXIDASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955414441     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-010-0964-z     Document Type: Article

References (28)

1. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 417 429 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D 12167685 (Pubitemid 34851835)
2. BE Sands 2000 Therapy of inflammatory bowel disease Gastroenterology 118 S68 S82 10.1016/S0016-5085(00)70007-2 1:CAS:528:DC%2BD3cXhsV2juro%3D 10868899
3. V Villanacci G Bassotti R Nascimbeni E Antonelli M Cadei S Fisogni B Salerni K Geboes 2008 Enteric nervous system abnormalities in inflammatory bowel diseases Neurogastroenterol Motil 20 1009 1016 10.1111/j.1365-2982.2008.01146.x 1:STN:280:DC%2BD1crivFKgtA%3D%3D 18492026
4. M Schemann M Neunlist 2004 The human enteric nervous system Neurogastroenterol Motil 16 55 59 10.1111/j.1743-3150.2004.00476.x 15066006 (Pubitemid 38580942)
5. GBT von Boyen M Reinshagen M Steinkamp G Adler J Kirsch 2002 Gut inflammation modulated by the enteric nervous system and neurotrophic factors Scand J Gastroenterol 37 621 625 10.1080/00365520212498 (Pubitemid 34620920)
6. H Hassani G Lucas B Rozell P Ernfors 2005 Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling Am J Physiol Gastrointest Liver Physiol 288 G550 G556 10.1152/ajpgi.00182.2004 1:CAS:528:DC%2BD2MXisVKqtr0%3D 15499082 (Pubitemid 40261755)
7. B Chandrasekharan V Bala VL Kolachala M Vijay-Kumar D Jones AT Gewirtz SV Sitaraman S Srinivasan 2008 Targeted deletion of neuropeptide Y (NPY) modulates experimental colitis PLoS ONE 3 e3304 10.1371/journal.pone.0003304 18836554
8. J Wheway H Herzog F Mackay 2007 NPY and receptors in immune and inflammatory disease Curr Top Med Chem 7 1743 1752 10.2174/156802607782341046 1:CAS:528:DC%2BD2sXhsVOrtbjM 17979783 (Pubitemid 350131011)
9. M Dimitrijevic S Stanojevic V Vujic A Beck-Sickinger S von Horsten 2005 Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage function in vitro: counter regulation through Y1 and Y2/5 receptors Regul Pept 124 163 172 10.1016/j.regpep.2004.07.012 1:CAS:528: DC%2BD2cXpslGmsbk%3D 15544855 (Pubitemid 39488355)
10. CP Sung AJ Arleth GZ Feuerstein 1991 Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes Circ Res 68 314 318 1:CAS:528:DyaK3MXkt1Omsr4%3D 1670626
11. JR Zhou XU Zheng LJ Chun 2008 Neuropeptide Y promotes TGF-β1 production in Raw 264. 7 cells by activation PI3K pathway via Y1 receptor Neurosci Bull 24 155 159 10.1007/s12264-008-0130-6 1:CAS:528: DC%2BD1MXntFOmt78%3D 18500388 (Pubitemid 352020329)
12. JA Custin ON Ozes H Akca R Pincheira D Mayo Q Li JR Guzman CK Korgaonkar DB Donner 2004 Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation J Biol Chem 279 1615 1620
13. RH Straub H Herfarth W Falk T Andus J Scholmerich 2002 Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 126 116 125 10.1016/S0165-5728(02) 00047-4 1:CAS:528:DC%2BD38XjvVaqt7s%3D 12020963 (Pubitemid 34521737)
14. S Agrwal Q Zhao 1998 Antisense therapeutics Curr Opin Chem Biol 2 519 528 10.1016/S1367-5931(98)80129-4
15. KF Pirollo A Rait LS Sleer EH Chang 2003 Antisense therapeutics: from theory to clinical practice Pharmacol Ther 99 55 77 10.1016/S0163-7258(03)00053- 6 1:CAS:528:DC%2BD3sXksVegsrw%3D 12804699 (Pubitemid 36694750)
16. NM Dean CF Bennett 2003 Antisense oligonucleotide-based therapeutics for cancer Oncogene 8 9087 9096 10.1038/sj.onc.1207231 (Pubitemid 38121709)
17. N Tomita R Morishita 2004 Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases Curr Pharm Des 10 797 803 10.2174/1381612043452965 1:CAS:528:DC%2BD2cXhvFOkur0%3D 15032704 (Pubitemid 38292407)
18. A Akabayashi C Wahlestedt JT Alexander SF Leibowitz, et al. 1994 Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion Mol Brain Res 21 55 61 10.1016/0169-328X(94)90377-8 1:STN:280:DyaK2c3hslCksQ%3D%3D 8164522 (Pubitemid 124014736)
19. B Xu A Sahu PS Kalra WR Crowley SP Kalra 1996 Disinhibition from opioid influence augments hypothalamic neuropeptide Y (NPY) gene expression and pituitary luteinizing hormone release: effects of NPY messenger ribonucleic acid antisense oligodeoxynucleotides Endocrinology 137 1 78 84 10.1210/en.137.1.78 1:CAS:528:DyaK28XhsVOltA%3D%3D 8536645 (Pubitemid 26004976)
20. SNS Murthy HS Cooper H Shim RS Shah SA Ibrahim DJ Sedergran 1993 Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin Dig Dis Sci 38 1722 1734 10.1007/BF01303184 1:CAS:528: DyaK2cXht1Cnsbs%3D 8359087
21. T ten Hove B van den Blink I Pronk, et al. 2002 Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis Gut 50 507 512 10.1136/gut.50.4.507 11889071 (Pubitemid 34638870)
22. HS Cooper SNS Murthy RS Shah DJ Sederqran 1993 Clinicopathologic study of dextran sulfate sodium experimental murine colitis Lab Invest 69 238 249 1:CAS:528:DyaK2cXhs1Smtr0%3D 8350599
23. KA Papadakis SR Targan 2000 Role of cytokines in the pathogenesis of inflammatory bowel disease Annu Rev Med 51 289 298 10.1146/annurev.med.51.1.289 1:CAS:528:DC%2BD3cXisVeltr4%3D 10774465 (Pubitemid 30216038)
24. A Mantovani M Muzio C Garlanda S Sozzani P Allavena 2001 Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines Novartis Found Symp 234 120 131 10.1002/0470868678.ch8 1:CAS:528:DC%2BD38Xht1OmtLg%3D 11199092
25. C Thukral A Cheifetz MA Peppercorn 2006 Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date Drugs 16 2059 2065 10.2165/00003495-200666160-00002 (Pubitemid 46372357)
26. H Ogata T Hibi 2003 Cytokine and anti-cytokine therapies for inflammatory bowel disease Curr Pharm Des 9 1107 1113 10.2174/1381612033455035 1:CAS:528:DC%2BD3sXivVemtLo%3D 12769750 (Pubitemid 36443211)
27. BG Feagan W Reinisch P Rutgeerts, et al. 2007 The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients Am J Gastroenterol 102 794 802 10.1111/j.1572-0241.2007.01094.x 1:CAS:528: DC%2BD2sXltlOgsL0%3D 17324131 (Pubitemid 46496629)
28. TS Blackwell JW Christman 1997 The role of nuclear factor-κB in cytokine gene regulation Am J Respir Cell Mol Biol 17 3 9 1:CAS:528: DyaK2sXksF2ktL8%3D 9224203